Acadia Pharmaceuticals has acquired Texas biotech CerSci Therapeutics, a privately held company with a clinical-stage molecule under evaluation as a potential therapy for post-surgical and nerve pain.
The San Diego-based company splashed out $52.5 million on the buyout, a cash-and-stock deal—$47.2 million of it in Acadia shares, according to a regulatory filing—that closed Monday. Acadia agreed to pay CerSci shareholders up to $887 million more in payments depending on development, commercialization, and sales milestones, plus royalties.
The acquisition adds a new element to the Acadia Pharmaceuticals (NASDAQ: ACAD) pipeline, the centerpiece of which is pimavanserin (Nuplazid), the drug the… Read more »
UNDERWRITERS AND PARTNERS
